101 Therapeutics
Developing Cures for Multiple Infectious Diseases
Company Overview
Snapshot
Founded in November 2020 by Alec Goldberg and James Goldberg, 101 Therapeutics operates with 1–10 employees. The company secured its first disclosed funding round in April 2023 from one investor, Awz Ventures, to advance its drug development efforts.
Business overview
101 Therapeutics is a Health Tech & Life Sciences company focused on developing treatments for various infectious diseases. The company's core technology involves a targeted glucocorticoid designed to offer the potency of steroids without systemic toxicities. By targeting the host immune system rather than specific pathogens, 101 Therapeutics aims to effectively treat a wide range of viral, parasitic, and bacterial infections. Operating in the Pharma & Medical Biotechnology sector, the company serves the Life Sciences and Pharmaceuticals markets with its drug discovery and development initiatives.
Strategic signal
In May 2023, 101 Therapeutics signed a Memorandum of Understanding (MoU) with CSIR-IICT for a new drug targeting Covid-19. This collaboration signals a strategic move to leverage external research capabilities and accelerate the development of their therapeutic candidates, indicating a proactive approach to addressing significant global health challenges and expanding their product pipeline.
Company Intelligence Q&A
- When was 101 Therapeutics founded?
- 101 Therapeutics was founded in November 2020 by Alec Goldberg and James Goldberg.
- What is the primary focus of 101 Therapeutics?
- 101 Therapeutics focuses on developing targeted glucocorticoids to treat multiple infectious diseases by modulating the host immune system, applicable to viral, parasitic, and bacterial infections.
- Has 101 Therapeutics engaged in any significant partnerships?
- In May 2023, 101 Therapeutics signed an MoU with CSIR-IICT to develop a new drug for Covid-19.
- What is the current employee count for 101 Therapeutics?
- 101 Therapeutics currently has 1–10 employees.
- Which investor participated in 101 Therapeutics' funding round?
- In April 2023, Awz Ventures participated in 101 Therapeutics' seed funding round.